- Case report
- Open Access
Orbital metastases as first sign of metastatic spread in breast cancer: Case report and review of the literature
© Eckardt et al; licensee BioMed Central Ltd. 2011
- Received: 4 August 2011
- Accepted: 22 August 2011
- Published: 22 August 2011
Intraorbital metastases of breast cancer is rare with only 3-10% of all ocular metastases. We report a case of orbital metastases as first sign of systemic metastatic spread in a female patient with breast cancer.
The patient had been diagnosed with breast cancer 3 years before. Her present complain was local pain, diplopia and periorbital swelling. A CT scan revealed extensive bony destruction of the orbital roof/anterior skull base. Bone scintigraphy demonstrated additional uptake at the level of the skull base, cervical spine, ilium and ribs suggesting metastatic spread to the skeleton. A navigation-assisted intraorbital biopsy from the orbital roof revealed a metastasis of breast cancer. With the confirmed diagnosis of metastatic breast cancer the patient was refered to the oncologist for further tumor staging. As further treatment she received systemic palliative chemotherapy in addition to intravenous treatment with bisphosphonates.
In patients with a previous history of breast cancer who complain even of mild ophthalmologic symptoms such as local pain, periorbital edema, it is important to consider ocular or orbital metastatic disease. Adequate 3D-Imaging followed by a biopsy will usually confirm the diagnosis.
- Orbital metastasis
- breast cancer
- navigation-assisted surgery
Orbital metastases occur in 2% to 3% of patients with cancer. Metastases of breast cancer account for the majority of ocular and orbital metastases . Clinical signs and symptoms may include proptosis, diplopia, pain, exopthalmus, blurred vision and a visible or palpable tumor mass in the orbital or periorbital region. The overall prognosis of patients with orbital metastasis is generally poor. In 12-31% of the affected patients [2–4] eye metastases are the first sign of malignant disease or metastatic spread. Once the diagnosis has been established treatment is mainly with palliative intention and focuses on symptom relief and improvement of orbital function as long as possible.
We report a case in which orbital metastasis of breast cancer was diagnosed with a navigation-assisted surgical biopsy. Further clinical staging revealed previously unknown multifocal skeletal metastasis.
In addition diagnosis and treatment concepts of orbital metastases will be reported.
A 73-year old woman presented with a 3-week history of left orbital pain with slight exophthalmus. Three years before the patient had been diagnosed with breast carcinoma cT4 cN1. The tumor was ER/PR positive and HER2-neu negative. The initial treatment consisted of neoadjuvant chemotherapy with epirubicin/cyclophosphamide (EC-protocol) followed by surgical tumor ablation and dissection of the left axilla. Postoperative external beam radiation of the thoracic wall was performed. After completion of the initial treatment with complete remission the patients further clinical course was uneventful. Due to the positive receptor status antihormonal therapy with anastrozole was initiated.
Typical manifestations of orbital metastases include a palpable mass causing displacement or proptosis of the globe, pain, inflammation, bone involvement, chemosis, and eyelid swelling .
Metastases to the eye and orbit have been described for a variety of solid tumors, but breast carcinoma accounts for the majority of ocular and orbital metastases [6–9]. In breast cancer - the most frequent cause of cancer-related death in women  - orbital metastases have been described in large studies in the range from 28.5-58.8% [1, 11, 12]. Orbital metastases from breast cancer tend to infiltrate the extraocular muscle and surrounding orbital fat, causing motility deficits. The histology features of adenocarcinoma of the breast vary, and the histologic features of orbital metastases may differ from the primary tumor.
Patients who have been diagnosed with orbital metastases usually carry a poor prognosis: the mean survival after diagnosis of such metastases is 31 months (range, 1-116 months) . Even if the orbit is the only clinical suspected site of metastatic involvement, the likelihood of further distant metastases in other organs is high as was shown in our patient following further staging procedures.
Treatment of orbital metastases aims at improving patient's quality of life and restore or preserve visual function. Usually treatment of orbital and ocular metastases is palliative and may include radiotherapy, systemic chemotherapy, hormonal therapy, or surgery in selected patients.
Radiotherapy is the mainstay for orbital and ocular metastases and appears to be safe and effective with objective response rates up to 79% . Radiotherapy improves symptoms in 80% of cases and restores vision in some cases . However, cataract formation and radiation retinopathy are potential side effects of external beam radiotherapy; these potential sequelae must be balanced against the overall prognosis and survival of the individual patient [12, 16]. Systemic chemotherapy is another mainstay in the palliative setting of orbital metastases; in addition the initiation of bisphosphonate treatment is important if osseous metastasis have been diagnosed. Novel targeted systemic treatments are increasingly used in addition to cytostatic chemotherapy. Recently, one case of dramatic local response of a unilateral choroidal metastasis in Her2/neu-positive breast cancer to systemic therapy with trastuzumab and vinorelbine was reported .
In general, extensive orbital surgery to remove the metastasis is not recommended as this is not curative and may be associated with significant ocular morbidity . Enucleation or rather radical measures offer no advantages in terms of progression or survival and should only be used in cases of intractable ocular pain or unmanageable local hygiene due to rapid tumor growth . The only appropriate surgical intervention for breast carcinoma metastatic to the orbit is a biopsy to establish the diagnosis .
In summary, although rare, breast cancer patients can develop metastases to the orbital and ocular region. Patients with a history of breast cancer presenting with ocular symptoms such as ptosis, proptosis, diplopia, pain, exophthalmus should be evaluated for orbital metastases. Once diagnosis is confirmed treatment for patients with orbital metastases is multidisciplinary.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The article processing charges are funded by the Deutsche Forschungsgemeinschaft (DFG), "Open Access Publizieren".
- Font RL, Ferry AP: Carcinoma metastatic to the eye and orbit. III. A Clinicopathologic study of 28 Cases Metastatic to the Orbit. Cancer. 1976, 38: 1326-1335. 10.1002/1097-0142(197609)38:3<1326::AID-CNCR2820380336>3.0.CO;2-#.View ArticlePubMedGoogle Scholar
- Ferry AP, Font RL: Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. Arch Ophthalmol. 1974, 92: 2766-286.View ArticleGoogle Scholar
- Glazer LC, Harris GJ, Simons KB: Orbital metastasis as the presenting sign of adenocarcinoma of the breast. Ophthal Plast Reconstr Surg. 1991, 7: 252-255. 10.1097/00002341-199112000-00003.View ArticlePubMedGoogle Scholar
- Reeves D, Levine MR, Lash R: Nonpalpable breast presenting as orbital infiltration: case presentation and literature review. Ophthal Plast Reconstr Surg. 2002, 18: 84-88. 10.1097/00002341-200201000-00014.View ArticlePubMedGoogle Scholar
- Mehdi Ahmad S, Esmaeli B: Metastatic tumors of the orbit and ocular adnexa. Curr Opin Ophthalmol. 2007, 18: 405-413. 10.1097/ICU.0b013e3282c5077c.View ArticlePubMedGoogle Scholar
- Ng E, Ilsen PF: Orbital metastases. Optometry. 2010, 81: 647-657.View ArticlePubMedGoogle Scholar
- Freedman MI, Folk JC: Metastatic tumors to the eye and orbit. Patient survival and clinical characteristics. Arch Ophthalmol. 1987, 1215-1219.Google Scholar
- Jakobiec F, Rootman J, Jones I: Secondary and metastatic tumors of the orbit. Clin Ophthalmol. 1998, 2: 51-64.Google Scholar
- de Potter P: Ocular manifestations of cancer. Curr Opin Ophthalmol. 1998, 9: 100-104. 10.1097/00055735-199812000-00018.View ArticlePubMedGoogle Scholar
- Dieing A, Schulz CO, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K: Orbital metastases in breast cancer: report of two cases and review of the literature. J Cancer Res Clin Oncol. 2004, 130: 745-748. 10.1007/s00432-004-0606-3.View ArticlePubMedGoogle Scholar
- Shields JA, Shields CL, Scartozzi R: Survey of 1264 patients with orbital tumors and simulating lesions. The Montgomery Lecture, Part I. Ophthalmology. 2004, 111: 997-108. 10.1016/j.ophtha.2003.01.002.View ArticlePubMedGoogle Scholar
- Amichetti M, Caffo O, Minatel E, Roncadin M, Valli MC, Lozza L, Panizzoni G: Ocular metastases from breast carcinoma: A multicentric retrospective study. Oncol Rep. 7: 761-766.Google Scholar
- Garrity JA, Henderson JW, Cameron JD: Metastatic carcinomas. Henderson's orbital tumors. 2007, New York: Raven Press, 313-326. 4Google Scholar
- Ratanatharathorn V, Powers WE, Grimm J, Steverson N, Han I, Ahmad K, Lattin PB: Eye metastasis from carcinoma of the breast: diagnosis, radiation treatment and results. Cancer Treat Rev. 1991, 18: 261-276. 10.1016/0305-7372(91)90017-T.View ArticlePubMedGoogle Scholar
- Char DH, Miller T, Kroll S: Orbital metastases: diagnosis and course. Br J Ophthalmol. 1997, 81: 386-390. 10.1136/bjo.81.5.386.PubMed CentralView ArticlePubMedGoogle Scholar
- Glassburn JR, Klionsky M, Brady LW: Radiation therapy for metastatic disease of the orbit. Am J Clin Oncol. 1984, 7: 145-148. 10.1097/00000421-198404000-00008.View ArticlePubMedGoogle Scholar
- Wong ZW, Philipps SJ, Ellis MJ: Dramatic response of choroidal metastases from breast cancer in combination of trastuzumab and vinorelbine. Breast J. 2004, 10: 54-56. 10.1111/j.1524-4741.2004.09614.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.